Mode
Text Size
Log in / Sign up
N/A N=16 Randomized Double-blind Treatment

Cathodal tDCS in MCI: A Randomized, Double-Blind, Sham-Controlled Pilot Study

Mild Cognitive Impairment · Cognitive Impairment · Neurocognitive Dysfunction

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Change in Flanker Inhibitory Control and Attention Test Scores — 35.1; 41.5 score on a scale — p=0.0039

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001 (Device)
Age
Adult, Older Adult · 55+ yrs
Sex
All
Sponsor
Mayo Clinic
Primary completion
May 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Flanker Inhibitory Control and Attention Test Scores
35.1; 41.5 0.0039 sig
PRIMARY
Change in Picture Vocabulary Test Scores
52.0; 52.0 0.9674
PRIMARY
Change in List Sorting Working Memory Test Scores
60.5; 51.8 0.0067 sig
PRIMARY
Change in Dimensional Change Card Sort Test
43.7; 48.0 0.3069
PRIMARY
Change in Pattern Comparison Processing Speed Test Scores
46.6; 51.6 0.2609
PRIMARY
Change in Picture Sequence Memory Test v2.1 Score
45.2; 42.8 0.6951
PRIMARY
Change in Oral Reading Recognition Test Score
58.5; 56.1 0.3592

Summary

This study evaluates the application of non-invasive brain stimulation in the treatment of Mild Cognitive Impairment (MCI) in adults aged 55-85. Half of the participants will receive transcranial direct current stimulation (tDCS), while the other half will receive sham (like placebo) stimulation.

Eligibility Criteria

Inclusion Criteria

  • Male or female outpatients with confirmed MCI diagnosis
  • Age 55-85
  • Right handed (tested using the Edinburgh handedness inventory)
  • Total PHQ-8 of ≤ 16 which signifies no severe depression
  • All participants and/or caregivers must be able to provide informed consent

Exclusion Criteria

  • Neurodegenerative disease (e.g. Parkinson's, Huntington's, Multiple Sclerosis) other than MCI
  • Previous brain lesion
  • Intracranial abnormality such as prior stroke
  • History of seizure disorder or epilepsy
  • A "true" positive response, after patient clarification, to any question on the modified TMS/tDCS Adult Safety Screen questionnaire that would impact patient safety
  • Any history of brain stimulation treatment (e.g., electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagal nerve therapy (VNS), deep brain stimulation (DBS))
  • Use of any investigational drug within 4 weeks
  • Cardiac pacemakers, implanted medication pumps, intracardiac lines; acute or unstable cardiac disease; intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head (exception: mouth/dental work) that cannot be safely removed
  • Known or suspected pregnancy (extremely unlikely as the age range for this study is 55-85 years)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03521089). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search